Navigation Links
Helix BioPharma shareholders vote in favour of management
Date:1/30/2008

Helix BioPharma Corp. (TSX: HBP / Frankfurt: WKN 918864)

AURORA, ON, Jan. 30 /PRNewswire-FirstCall/ - Helix BioPharma Corp. announces that at the Company's Annual General Meeting held on January 29th, 2008, shareholders adopted all of the resolutions presented by management, appointing KPMG LLP as auditor, electing Don Segal, John Docherty, Ken Cawkell, Jack Kay, Slawomir Majewski, and Gordon Lickrish as directors, and approving certain amendments to the Company's by-laws.

Joining the Helix BioPharma board is Professor Slawomir Majewski, Head of the Department of Dermatology and Venereology at the Warsaw School of Medicine in Poland. Professor Majewski's extensive experience in the field of dermatology, and especially sexually transmitted diseases and skin cancer, will be of great benefit to the Board of Directors and the senior management team at Helix.

Retiring from Helix's board are Conor Gunne and Dr. Richard Rossman, who served as directors of Helix for a number of years. "I would like to personally thank both Conor and Richard for their valuable contribution to the Company over the many years and wish them both well in their other endeavors," said Don Segal, CEO of Helix BioPharma.

Helix's management would also like to thank its shareholders for their continued support, and looks forward to the further development of the Company's new drug products, Topical Interferon Alpha-2b and L-DOS47, in the year ahead.

A Report of Voting Results in respect of the Meeting will be posted on the SEDAR website at (http://www.sedar.com).

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP" and quoted on the Frankfurt, Berlin, Munich and Stuttgart Stock Exchanges under the same symbol.

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release. This News Release contains forward-looking statements regarding the development of the Company's drug products, which statements can be identified by the words "looks forward, "development" and "developing". Actual results or events could differ materially from these forward-looking statements and information due to numerous factors, including without limitation, research & development risks, intellectual property risks; product liability risks; the risk of unanticipated expenses, the need for regulatory approvals which is not assured; the need for clinical trials and uncertainty whether they will occur or will be successful; and possible changes in business strategy or plans. These and other risks and uncertainties are contained in Helix's latest Annual Information Form at http://www.sedar.com. Forward-looking statements and information are based on the assumptions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation, except as required by law, to update any forward-looking statement or information should those assumptions or expectations, or other circumstances change.


'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
11. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology:
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
(Date:3/22/2016)... , PROVO and ... -- Newborn Screening Ontario (NSO), which operates the highest ... for molecular testing, and Tute Genomics and UNIConnect, leaders ... technology respectively, today announced the launch of a project ... sequencing (NGS) testing panel. NSO has ...
Breaking Biology News(10 mins):